Can You Test for Ketamine? Detection Methods & Windows

Ketamine is detectable in urine, blood, saliva, and hair using a range of laboratory techniques, though it does not show up on most standard workplace drug panels. Detection windows span from hours in blood to months in hair, and the specific method used matters enormously. Because ketamine prescriptions for depression and pain management have surged alongside rising recreational use, testing for it has become a more common question for patients, employers, and forensic investigators alike.

Urine Testing and How Long Ketamine Stays Detectable

Urine is the most frequently used sample type for ketamine detection, largely because collection is straightforward and the detection window is longer than in blood. When your body processes ketamine, the liver converts it first into norketamine, and then into a further breakdown product called dehydronorketamine. All three compounds end up in urine, and labs look for them in combination because the metabolites persist longer than the parent drug itself.

Exactly how many days ketamine or its metabolites remain detectable in urine depends heavily on the analytical method. One study using ultra-high-pressure liquid chromatography with mass spectrometry confirmed ketamine in urine for up to five days after a dose, norketamine for six days, and dehydronorketamine for up to ten days.¹ A separate study in children receiving therapeutic ketamine found even wider variation: depending on the analytical technique, norketamine was detectable anywhere from six to fourteen days after the last dose, and ketamine itself was found as late as eleven days with one method but only two days with another.² In that same study, one child never produced a positive ketamine result across the entire sixteen-day collection period despite having received the drug, underscoring how much individual biology shapes results.

For a rough rule of thumb, most clinical guidance puts the urine detection window for ketamine at about two to four days for the parent drug and up to two weeks if the lab specifically tests for norketamine or dehydronorketamine. But those numbers shift with dose, frequency of use, the person’s metabolism, and the sensitivity of the test.

Blood and Oral Fluid Testing

Blood testing offers a much shorter detection window than urine, typically measured in hours rather than days. Ketamine’s effects peak quickly after administration and blood levels drop fast. A phase 1 trial of oral ketamine capsules in healthy adults found that mood and dissociative effects appeared about an hour after dosing and returned to baseline within roughly four hours, which tracks with how rapidly the drug clears from plasma.³ The practical upshot is that blood tests are useful mainly in acute situations like emergency rooms, traffic stops, or forensic investigations close in time to suspected use.

Oral fluid, or saliva, is increasingly used in roadside drug testing because it is easy to collect and reflects recent drug intake. A study of drivers in northeastern France found ketamine in oral fluid samples at concentrations sometimes exceeding 300 ng/mL, alongside its metabolite norketamine.⁴ Oral fluid generally reflects a detection window of roughly one to two days, though this depends on dose and individual factors. Its main advantage is that collection is non-invasive and can be observed to prevent tampering, making it popular for law enforcement.

One practical detail worth knowing: ketamine and norketamine remain stable in whole blood for at least 120 hours at both room temperature and refrigerated conditions, meaning that delays in transporting a blood sample to a lab are unlikely to cause a false negative.⁵

Hair Testing for Longer-Term Detection

Hair analysis extends the detection window far beyond what any body fluid can offer. As hair grows, drugs circulating in the bloodstream get incorporated into the hair shaft, creating a timeline of past use that can stretch back months. For ketamine, hair testing is used mainly in forensic investigations and chronic-use monitoring rather than everyday clinical screening.

A case study tracking a patient after ketamine treatment was stopped found the drug was still detectable in hair more than four months after cessation, with an estimated elimination half-life in hair of about 0.88 months. The researchers projected that ketamine would reach undetectable levels roughly seven months after the last exposure.⁶ That is a vastly longer window than any other sample type.

Segmental hair analysis can go further still, revealing patterns of use over time. By cutting hair into segments and analyzing each one separately, a lab can estimate when drug use occurred and whether it was ongoing or sporadic.⁷ To distinguish regular users from people with incidental environmental exposure, researchers have proposed a concentration cutoff of 0.5 ng/mg of hair as a threshold for repeated ketamine use.⁸ Validated laboratory methods exist that meet this threshold reliably.⁹

Why Standard Drug Panels Often Miss Ketamine

If you have taken a standard five-panel or even ten-panel workplace drug test, ketamine was almost certainly not on it. The most common employment and federal screening panels test for marijuana, cocaine, opioids, amphetamines, and PCP. Extended panels add things like benzodiazepines and barbiturates but still typically leave ketamine off the list. This is partly historical: when these panels were designed, ketamine misuse was much less prevalent than it is now.

That said, labs can add ketamine to a panel when specifically requested. Immunoassay screening kits designed for ketamine exist, and at least one validated ELISA method uses a cutoff of 25 ng/mL, achieving perfect sensitivity and specificity when compared against confirmatory mass spectrometry results.¹⁰ Newer-generation immunoassays have also shown strong accuracy, correctly identifying all negative samples and all confirmed positive samples in comparison studies.¹¹ The bottom line is that ketamine testing is technically robust, but you will not encounter it unless someone specifically orders it.

For the most sensitive and specific results, labs use liquid chromatography coupled with tandem mass spectrometry, which can achieve detection limits as low as 1 ng/mL for ketamine and its metabolites.¹² This kind of confirmatory testing is more expensive and takes longer than a rapid immunoassay, but it is the gold standard when results need to hold up in court or clinical decisions depend on them.

False Positives and the PCP Cross-Reactivity Problem

Here is a wrinkle that catches some people off guard: ketamine is structurally related to PCP (phencyclidine), and immunoassay-based PCP screens can sometimes flag positive in people who have taken ketamine but no PCP at all. Immunoassays work by recognizing molecular shape, and when two drugs share enough structural features, the antibodies in the test cannot always tell them apart. Research has shown that out-of-class drugs account for a high proportion of false positives on PCP immunoassay screens.¹³

This means that someone taking prescribed ketamine for depression or chronic pain could, in theory, produce a false positive on a PCP screen during a standard drug test. The fix is confirmatory testing by mass spectrometry, which can distinguish the two drugs with certainty. If you are a patient on ketamine therapy and face workplace testing, this is worth discussing with both your prescriber and your employer ahead of time. A positive PCP screen that is actually caused by ketamine will be resolved by confirmation testing, but the process can create unnecessary anxiety and delays.

Why Detection Windows Vary So Much Between People

One of the most underappreciated facts about ketamine testing is how dramatically metabolism differs from person to person. Ketamine is broken down in the liver primarily by two enzyme families, CYP3A4 and CYP2B6.¹⁴ Genetic variation in these enzymes can have a striking effect on how quickly you clear the drug.

People carrying certain variants of the CYP2B6 gene metabolize ketamine much more slowly. In a study of chronic pain patients, those with two copies of the CYP2B6*6 variant had a median plasma clearance of about 22 liters per hour, compared with roughly 68 liters per hour in those with the normal genotype. That is more than a threefold difference in how fast the drug leaves the body.¹⁵ Age compounds the effect: older adults tend to clear ketamine more slowly regardless of genotype. Research on CYP2B6 variants has confirmed that these genetic differences reduce the enzyme’s ability to convert ketamine into norketamine, directly affecting both the drug’s duration of action and how long it remains detectable.¹⁶

What this means in practice is that two people given the same dose of ketamine on the same day could have very different testing outcomes a few days later. One might test clean while the other still has detectable levels. Frequency of use matters too: someone using ketamine regularly will accumulate more drug and metabolites in their system than a one-time user, pushing the detection window further out.

Telling Prescribed Ketamine From Street Ketamine

An increasingly relevant question in forensic and clinical toxicology is whether a lab can determine not just that someone used ketamine, but what kind. Prescription esketamine (the S-enantiomer, marketed as Spravato for depression) is a single mirror-image form of the molecule, whereas street ketamine is almost always a racemic mixture of both mirror-image forms in roughly equal amounts.

Chiral analysis methods can now distinguish between these. A recently validated technique using ultra-high-performance liquid chromatography with mass spectrometry separated ketamine’s two enantiomers in both urine and hair. In a case where a person had used only prescription esketamine before death, only S-ketamine was found in blood and urine, confirming that the drug does not flip from one mirror form to the other inside the body. Meanwhile, hair samples from 45 people who used illicit ketamine showed a ratio of the two forms ranging from about 0.8 to 1.4, consistent with racemic street product.¹⁷

This distinction has real legal and clinical implications. A patient prescribed esketamine who tests positive for ketamine can, with the right lab work, demonstrate that their exposure is consistent with prescribed use. Conversely, the presence of both enantiomers in equal proportions points toward illicit sourcing. Not every lab offers this analysis, but it is available and validated for forensic casework.

Driving Under the Influence and Legal Thresholds

Ketamine is increasingly relevant in drug-impaired driving cases. A study of impaired driving cases in the Cologne area found ketamine plasma concentrations ranging from about 100 to 1,200 ng/mL among suspected drivers, with a median of 370 ng/mL. Recorded impairments included dilated pupils, slurred or slowed speech, delayed reactions, poor concentration, and vertigo. Every single driver in that study also had at least one other substance in their system, making ketamine-only impairment data hard to isolate.¹⁸

Legal thresholds for ketamine and driving vary by jurisdiction. Some countries have per se limits, meaning any detectable amount above a set concentration is illegal regardless of observed impairment. Others require evidence of actual impairment alongside a positive test. Because ketamine’s subjective effects wear off in a few hours while detectable blood levels can linger longer, a positive blood test does not always mean the person was impaired at the time of driving. This gap between detection and impairment is a persistent challenge in drug-driving prosecution.

Postmortem and Forensic Investigation Testing

Testing for ketamine after death comes with its own complications. A phenomenon called postmortem redistribution can cause drug concentrations to shift between body compartments after the heart stops pumping. In ketamine cases, researchers have observed marked differences between heart blood and femoral (leg) blood concentrations, which could reflect either incomplete distribution before death or drug movement between tissues afterward.¹⁹

To address this, forensic toxicologists have explored alternative sample types. One study examined ketamine levels in ocular matrices (the fluids inside the eye), finding that ketamine levels in those fluids tended to increase slightly after death while blood levels decreased, though most of these changes were not statistically significant.²⁰ Eye fluid is considered more resistant to postmortem redistribution than blood, making it a useful supplementary specimen in death investigations.

Emerging Testing Approaches

Beyond the established methods in urine, blood, saliva, and hair, newer technologies are being developed. Fingerprint-based drug testing, which collects trace amounts of sweat deposited in a fingerprint, has been adapted to include ketamine. One system uses a small cartridge to collect a fingerprint sweat sample in under a minute and delivers results for multiple drug groups in about ten minutes on-site. The approach is non-invasive and difficult to tamper with, since the collection process is quick and observed. Development of ketamine-specific assays for this platform is ongoing as manufacturers expand their drug panels to keep pace with shifting patterns of use.

Designer analogs of ketamine pose another challenge for testing. Compounds like deschloroketamine share structural features with ketamine but differ enough that standard immunoassays may not pick them up. Identifying these analogs requires advanced analytical methods like high-resolution mass spectrometry, which can distinguish them from ketamine based on precise molecular weight and fragmentation patterns.²¹ As new ketamine-like substances appear on the market, forensic labs are in a constant race to update their methods. A screening test designed for ketamine alone will not reliably catch these analogs unless the lab has specifically validated for them, which is something worth keeping in mind if you are involved in forensic or compliance work where novel substances are a concern.